Brokerages Set Heron Therapeutics Inc (HRTX) Price Target at $31.13
Shares of Heron Therapeutics Inc (NASDAQ:HRTX) have been assigned a consensus recommendation of “Buy” from the thirteen analysts that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $31.13.
HRTX has been the topic of several analyst reports. Mizuho reissued a “buy” rating and set a $28.00 target price on shares of Heron Therapeutics in a report on Tuesday, November 7th. Cowen reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Heron Therapeutics in a research note on Monday, November 6th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Heron Therapeutics in a research note on Thursday, November 2nd. Oppenheimer assumed coverage on Heron Therapeutics in a research note on Monday, October 30th. They issued a “buy” rating and a $27.00 price objective on the stock. Finally, Noble Financial reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Heron Therapeutics in a research note on Friday, October 6th.
In related news, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 19.93% of the company’s stock.
Heron Therapeutics (NASDAQ:HRTX) traded up $0.30 on Friday, hitting $23.20. The stock had a trading volume of 935,200 shares, compared to its average volume of 1,120,538. The firm has a market cap of $1,270.00, a price-to-earnings ratio of -6.12 and a beta of 2.12. Heron Therapeutics has a 12 month low of $12.25 and a 12 month high of $23.35. The company has a current ratio of 2.12, a quick ratio of 2.02 and a debt-to-equity ratio of 0.62.
Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to analyst estimates of $8.12 million. Heron Therapeutics had a negative return on equity of 385.11% and a negative net margin of 831.89%. equities analysts anticipate that Heron Therapeutics will post -3.38 EPS for the current year.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.